Paracetamol Market Research Report [2022-2028] | Industry Size, Share, Growth Rate| Business Strategies, Industry Revenue, Opportunities, Future Trends, Leading Players Update, Analysis and Forecast | Market Reports World
February 15, 2022 01:27 ET
|
Market Reports World
Pune, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Global Paracetamol Market 2022 research report represents a detailed overview of the current market situation and forecast till 2028. The study is perhaps a...
Worldwide Paracetamol Industry to 2026 - Cold and Cough Segment is Dominating the Paracetamol Market
October 07, 2021 04:48 ET
|
Research and Markets
Dublin, Oct. 07, 2021 (GLOBE NEWSWIRE) -- The "Paracetamol Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering. The...
Aladotes® resultat är utvald för presentation på The International Liver Congress
January 31, 2019 02:00 ET
|
PledPharma AB
Stockholm, 31 januari 2019. PledPharma AB (publ) meddelar att abstraktet med de positiva resultaten från Aladotes® Fas Ib/IIa proof of principle-studie har utvalts för muntlig presentation på den...
Aladote®’s data has been selected for presentation at The International Liver Congress
January 31, 2019 02:00 ET
|
PledPharma AB
Stockholm, January 31, 2019. PledPharma AB (publ) announces that the abstract on the positive results from the Aladote®’s Phase Ib/IIa proof of principle-study has been selected for an oral...
PledPharma applies for an Orphan Drug Designation (ODD) in the US for Aladote
December 24, 2018 02:00 ET
|
PledPharma AB
Stockholm, December 24, 2018. PledPharma AB (publ) announces that the company has filed an application for an Orphan Drug Designation (ODD) to the US FDA for the drug candidate Aladote®, developed to...
PledPharma har ansökt om särläkemedelsstatus (ODD) för Aladote i USA
December 24, 2018 02:00 ET
|
PledPharma AB
Stockholm, 24 december 2018. PledPharma AB (publ) meddelar att bolaget har lämnat in en ansökan till amerikanska läkemedelsmyndigheten FDA om särläkemedelsstatus (ODD, Orphan Drug Designation) för...
PledPharma presents results from study on drug candidate Aladote® for paracetamol poisoning at a global toxicology conference
December 13, 2018 02:00 ET
|
PledPharma AB
Stockholm, December 13, 2018. PledPharma AB (publ) announces that the company's Aladote® Phase Ib/IIa study results has been accepted for a poster presentation during the “58th Annual Meeting of the...
PledPharma presenterar resultat från studie på läkemedelskandidaten Aladote® för paracetamolförgiftning på global toxikologikonferens
December 13, 2018 02:00 ET
|
PledPharma AB
Stockholm, 13 december 2018. PledPharma AB (publ) meddelar att bolagets Aladote® fas Ib/IIa studieresultat har accepterats för presentation på den globala toxikologikonferensen ”58th Annual Meeting of...
Interim Report January-September 2018
October 23, 2018 02:00 ET
|
PledPharma AB
Summary JULY-SEPTEMBER IN BRIEF PledPharma announces positive results from the Aladote® proof of principle studyThe Scientific Advisory Board for Aladote® held its first meeting with focus...
Delårsrapport januari-september 2018
October 23, 2018 02:00 ET
|
PledPharma AB
SAMMANDRAG JULI-SEPTEMBER I KORTHET PledPharma redovisar positiva slutresultat från klinisk proof of principle-studie av Aladote®Det vetenskapliga rådet för Aladote® har haft sitt första...